Premium
[O3–10–03]: LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY
Author(s) -
Lleó Alberto,
Alcolea Daniel,
MartinezLage Pablo,
Scheltens Philip,
Parnetti Lucilla,
Poirier Judes,
Simonsen Anja H.,
Verbeek Marcel M.,
RosaNeto Pedro,
Slot Rosalinde E.R.,
Tainta Mikel,
Izagirre Andrea,
Reijs Babette L.R.,
Farotti Lucia,
Fortea Juan,
Frölich Lutz,
Santana Isabel,
Molinuevo José Luis,
Lehmann Silvain,
Visser Pieter Jelle,
Teunissen Charlotte E.,
Zetterberg Henrik,
Blennow Kaj
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.07.359
Subject(s) - cerebrospinal fluid , biomarker , medicine , cognitive decline , longitudinal study , dementia , apolipoprotein e , gastroenterology , alzheimer's disease , oncology , psychology , disease , pathology , chemistry , biochemistry
years, range 0.5-3.4 years), statistically significant increases over time were noted in sAPPa, sAPPb, Ab38, YKL-40, NFL, p-tau, and decreases in Ab40, Ab42, MCP-1, and neurogranin (all p<0.004) Changes in biomarkers correlated with time since baseline visit (Figure). APOE4 status had little effect on biomarker changes over time. Conclusions: In this analysis of cognitivelyhealthy middle-aged and older adults enriched for AD risk, longitudinal CSF changes over several years suggest early neuropathologic changes that are discordant from cross-sectional assessments of CSF biomarker associations with age. Further longitudinal followup is underway to further characterize the impact of these CSF biomarker changes on cognition and other clinical endpoints.